Novo Nordisk ADR [NVO] stock is trading at $65.16, up 4.06%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NVO shares have gain 8.76% over the last week, with a monthly amount drifted -5.97%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novo Nordisk ADR [NYSE: NVO] stock has seen the most recent analyst activity on April 17, 2025, when BMO Capital Markets downgraded its rating to a Market Perform but kept the price target unchanged to $64 for it. Previously, Kepler upgraded its rating to Buy on March 13, 2025. On March 03, 2025, downgrade downgraded it’s rating to Hold. Morgan Stanley started tracking the stock assigning a Equal-Weight rating. Bernstein upgraded its rating to a Mkt Perform. Goldman started tracking with a Buy rating for this stock on May 30, 2024, and assigned it a price target of $156. In a note dated April 12, 2024, BMO Capital Markets initiated an Outperform rating and provided a target price of $163 on this stock.
Novo Nordisk ADR [NVO] stock has fluctuated between $57.00 and $148.15 over the past year. Currently, Wall Street analysts expect the stock to reach $158 within the next 12 months. Novo Nordisk ADR [NYSE: NVO] shares were valued at $65.16 at the most recent close of the market. An investor can expect a potential return of 142.48% based on the average NVO price forecast.
Analyzing the NVO fundamentals
Novo Nordisk ADR [NYSE:NVO] reported sales of 42.09B for the trailing twelve months, which represents a growth of 29.02%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.44%, Pretax Profit Margin comes in at 0.44%, and Net Profit Margin reading is 0.35%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is 0.85 and Total Capital is 0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.72.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 64.41 points at the first support level, and at 63.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.66, and for the 2nd resistance point, it is at 66.16.
Ratios To Look Out For
For context, Novo Nordisk ADR’s Current Ratio is 0.74. Also, the Quick Ratio is 0.55, while the Cash Ratio stands at 0.07. Considering the valuation of this stock, the price to sales ratio is 5.21, the price to book ratio is 14.52 and price to earnings (TTM) ratio is 19.85.
